NCT05906745Completed
Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure.
Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure. (GOALS-HF)
Source: ClinicalTrials.gov · Last updated 19 Feb 2025
Brief summary (registry, in English)
A multicenter, non-randomized prospective longitudinal study to evaluate the feasibility of Tricog's Remote platform for Guideline Directed Medical Therapy (GDMT) titration and remote patient monitoring among patients with Heart Failure.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 52 (actual)
- First submitted
- 30 May 2023
- Start date
- 21 Jul 2023
- Primary completion date
- 27 Sept 2024
- Lead sponsor
- Tricog Health Inc
- Diseases
- Heart failure
- NCT number
- NCT05906745
What you commit to
- Study type: Observational
- Participants enrolled: 52
- From 21 Jul 2023 to the primary completion date, 27 Sept 2024
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or anticipated use of home intravenous inotrope therapy.
- Planned (within next 6 months) surgery
Other illness
- Under consideration for or recipient of advanced heart failure therapies (LVAD, Transplant)
Other
- Unwilling or unable to perform all study related procedures (wear watch, take measurements and maintain daily logs)
- Post-discharge placement in nursing, rehabilitation, or long-term care facility
- Inability to provide written consent
Who the study is looking for
- Age ≥ 18 years
- Recent hospitalization (within 4 weeks of enrollment) for HF with IV diuretic use
- Echocardiographic data with EF measurements available in the last 6 months and after HF diagnosis
- Established outpatient care at the participating sites
- Eligible to receive at least 2 of the 4 GDMT classes (ACEi/ARB/ARNi, Beta-blockers, MRA, and SGLT2i) for HFrEF and HFmrEF and at least one of the three (ARB/ARNI, MRA, SGLT2i) for HFpEF
- Not on Target GDMT for all the eligible GDMT classes
- \>12 months of expected survival
- Comfortable with spoken and written English communication
- Access to Apple Watch-compatible iPhone
Age in the registry: 18 years to - · Sex: All
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Manipal Hospital Coordinator of this site? Confirm its status | Bengaluru | India | Unknown status |
| Sakra World Hospital Coordinator of this site? Confirm its status | Bengaluru | India | Unknown status |
| UT Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.